[go: up one dir, main page]

GT200600262A - Uso de la sangliferina en el hcv (virus de la hepatitis "c") - Google Patents

Uso de la sangliferina en el hcv (virus de la hepatitis "c")

Info

Publication number
GT200600262A
GT200600262A GT200600262A GT200600262A GT200600262A GT 200600262 A GT200600262 A GT 200600262A GT 200600262 A GT200600262 A GT 200600262A GT 200600262 A GT200600262 A GT 200600262A GT 200600262 A GT200600262 A GT 200600262A
Authority
GT
Guatemala
Prior art keywords
sangliferine
hcv
hepatitis virus
hepatitis
sangliferines
Prior art date
Application number
GT200600262A
Other languages
English (en)
Inventor
Kai Lin
Beat Weidmann
Kaspar Zimmermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37075234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600262(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600262A publication Critical patent/GT200600262A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE CON LA UTILIZACIÓN DE MACRÓLIDOS, LLAMADOS CONJUNTAMENTE SANGLIFERINAS LOS CUALES SON DE UTILIDAD EN LA PREVENCIÓN O TRATAMIENTO DE LAS INFECCIONES POR HEPATITIS C.
GT200600262A 2005-06-17 2006-06-16 Uso de la sangliferina en el hcv (virus de la hepatitis "c") GT200600262A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69149705P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
GT200600262A true GT200600262A (es) 2007-03-28

Family

ID=37075234

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600262A GT200600262A (es) 2005-06-17 2006-06-16 Uso de la sangliferina en el hcv (virus de la hepatitis "c")

Country Status (21)

Country Link
US (1) US20090221598A1 (es)
EP (1) EP1893211B1 (es)
JP (1) JP2008546708A (es)
KR (1) KR20080033274A (es)
CN (1) CN101242842A (es)
AR (1) AR054778A1 (es)
AT (1) ATE524183T1 (es)
AU (1) AU2006259348B2 (es)
BR (1) BRPI0613142A2 (es)
CA (1) CA2611151A1 (es)
EC (1) ECSP078029A (es)
GT (1) GT200600262A (es)
MA (1) MA29600B1 (es)
MX (1) MX2007016068A (es)
NO (1) NO20080351L (es)
PE (1) PE20070118A1 (es)
RU (1) RU2427372C2 (es)
TN (1) TNSN07477A1 (es)
TW (1) TW200740438A (es)
WO (1) WO2006138507A1 (es)
ZA (1) ZA200710551B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962329B2 (en) 2008-09-24 2015-02-24 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Gene cluster
US20120295346A1 (en) * 2009-07-22 2012-11-22 Tufts University Methods and compositions for modulating membrane potential to influence cell behavior
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
BR112012019866A8 (pt) 2010-02-09 2017-12-26 Biotica Tech Limited Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
AR084217A1 (es) * 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CN107090476B (zh) 2010-12-20 2021-09-24 爱博利瓦有限公司 Sanglifehrin衍生物及其制备方法
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
WO2012145427A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
ES2656087T3 (es) * 2012-06-08 2018-02-23 Gilead Sciences, Inc. Inhibidores macrocíclicos de virus Flaviviridae

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
KR100217483B1 (ko) 1990-04-06 1999-09-01 프랭크 쿵 C형 간염 바이러스 에피토프
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
GB9318612D0 (en) 1993-09-08 1993-10-27 Sandoz Ltd An assay
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
IL134233A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
RU2180862C2 (ru) * 1999-11-30 2002-03-27 Научно-исследовательский институт клинической и экспериментальной лимфологии СО РАМН Способ лечения хронических вирусных гепатитов
RU2250768C2 (ru) * 2000-03-02 2005-04-27 Санг Геон КИМ Фармацевтическая композиция и способ лечения прогрессирующего фиброза и цирроза печени
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN100490818C (zh) 2000-05-26 2009-05-27 诺瓦蒂斯有限公司 β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
JP2004504407A (ja) 2000-07-21 2004-02-12 コルバス・インターナショナル・インコーポレイテッド Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
WO2002008187A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AU2001255070A1 (en) 2000-08-28 2002-03-13 Jin-Sub Kim Generator of two-wheeled vehicle and lighting system thereby
HUP0500456A3 (en) 2000-11-20 2012-05-02 Bristol Myers Squibb Co Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CA2580448C (en) * 2004-10-01 2012-09-18 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
CN101076350A (zh) * 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物

Also Published As

Publication number Publication date
MA29600B1 (fr) 2008-07-01
AU2006259348A1 (en) 2006-12-28
ECSP078029A (es) 2008-01-23
JP2008546708A (ja) 2008-12-25
EP1893211B1 (en) 2011-09-14
US20090221598A1 (en) 2009-09-03
WO2006138507A1 (en) 2006-12-28
ZA200710551B (en) 2008-11-26
BRPI0613142A2 (pt) 2010-12-21
NO20080351L (no) 2008-03-14
RU2427372C2 (ru) 2011-08-27
CN101242842A (zh) 2008-08-13
EP1893211A1 (en) 2008-03-05
AU2006259348B2 (en) 2010-07-22
RU2008100587A (ru) 2009-07-27
PE20070118A1 (es) 2007-02-23
KR20080033274A (ko) 2008-04-16
CA2611151A1 (en) 2006-12-28
ATE524183T1 (de) 2011-09-15
TNSN07477A1 (en) 2009-03-17
TW200740438A (en) 2007-11-01
AR054778A1 (es) 2007-07-18
MX2007016068A (es) 2008-03-10

Similar Documents

Publication Publication Date Title
DOP2009000094A (es) Inhibidores de la proteasa ns3 del hcv
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
PA8733401A1 (es) Compuestos de pirro[1,2-b]piridazinona
CY1111526T1 (el) Αναστολεις κυκλοπροπυλ συντηγμενης ινδολοβενζαζεπινης της ns5b του hcv
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
EA200701850A1 (ru) Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих
BR0305259A (pt) Inibidores de hcv ns5b polimerase
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
BRPI0414062B8 (pt) uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
CR11310A (es) Espiro-Pirrolidinas y su uso contra infeccion por el virus de Hepatitis C (HCV) y por el virus de Inmunodeficiencia Humana (VIH)
EA200700243A1 (ru) Способы лечения гепатита с
ATE483712T1 (de) Hcv-ns5b-inhibitoren
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
UA90909C2 (en) Hcv ns3 protease inhibitors
UY28580A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
GT200300239A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
UY28054A1 (es) Compuesto de benzofurano, composiciones y métodos para tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
DOP2005000262A (es) Compuestos de piridazinona